More on 02142
News
- Harbour BioMed and Sinopharm Enter Strategic Collaboration to Establish Innovation R&D Consortium
- Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable Growth
- Nona Biosciences Enters Research Collaboration with the Medical University of Vienna to Advance Fully Human Antibody Development for Infectious Diseases
- Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Asthma
- Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Asthma
- Nona Biosciences and Lonza Enter Strategic Collaboration to Develop Best-in-Class Single-Domain Antibody-Based BBB-Crossing Technology for CNS Diseases
- Harbour BioMed Appoints Dr. Lloyd Klickstein as Scientific Advisor for Immunology
- Harbour BioMed and BioMap Jointly Initiate MegaStream TechBio: A Leading Global Drug Development Platform Joins Forces with Premier Life Science Foundation Models to Set New Benchmarks for AI-Driven C
- Harbour BioMed wins $20.2 million patent case against Amgen
- Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape
Entities mentioned with 02142
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- Carl Icahn | View Related Stories »
- Twitter | View Related Stories »
- Credit Suisse | View Related Stories »
- Deutsche Bank | View Related Stories »
- UBS | View Related Stories »
- Show More...
